Fredrik Lehmann

ORCID

Publication Activity (10 Years)

Years Active: 2020-2022
Publications (10 Years): 6

Top Venues

Antibodies (Basel, Switzerland)

ChemMedChem

Cancers

Molecules (Basel, Switzerland)

Oncopeptides AB

University of Gothenburg (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Oncopeptides AB

Sweden

EVP Research and CMC :: Research and CMC

Education History

University of Gothenburg

Sweden

PHD :: Chemistry

Publications

Arjen Gebraad, Roope Ohlsbom, Juho J Miettinen, Promise Emeh, Toni-Karri Pakarinen, Mikko Manninen, Antti Eskelinen, Kirsi Kuismanen, Ana Slipicevic, Fredrik Lehmann, Nina N Nupponen, Caroline A Heckman, Susanna Miettinen
Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug Melflufen. Cells 11 (9) (2022)
Juho J Miettinen, Romika Kumari, Gunnhildur Asta Traustadottir, Maiju-Emilia Huppunen, Philipp Sergeev, Muntasir M Majumder, Alexander Schepsky, Thorarinn Gudjonsson, Juha Lievonen, Despina Bazou, Paul Dowling, Peter O Gorman, Ana Slipicevic, Pekka Anttila, Raija Silvennoinen, Nina N Nupponen, Fredrik Lehmann, Caroline A Heckman
Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen. Cancers 13 (7) (2021)
Rafael W Hartmann, Matthijs Pijnappel, Johan Nilvebrant, Hildur Run Helgudottir, Arni Asbjarnarson, Gunnhildur Asta Traustadottir, Thorarinn Gudjonsson, Per-Åke Nygren, Fredrik Lehmann, Luke R Odell
The Wittig bioconjugation of maleimide derived, water soluble phosphonium ylides to aldehyde-tagged proteins. Organic & biomolecular chemistry 19 (47) (2021)
Jakob Lindberg, Johan Nilvebrant, Per-Åke Nygren, Fredrik Lehmann
Progress and Future Directions with Peptide-Drug Conjugates for Targeted Cancer Therapy. Molecules (Basel, Switzerland) 26 (19) (2021)
Malin Källsten, Rafael W Hartmann, Lucia Kovac, Fredrik Lehmann, Sara Bergström Lind, Jonas Bergquist
Investigating the Impact of Sample Preparation on Mass Spectrometry-Based Drug-To-Antibody Ratio Determination for Cysteine- and Lysine-Linked Antibody-Drug Conjugates. Antibodies (Basel, Switzerland) 9 (3) (2020)
Rafael W Hartmann, Raphael Fahrner, Denys Shevshenko, Mårten Fyrknäs, Rolf Larsson, Fredrik Lehmann, Luke R Odell
Rational Design of Azastatin as a Potential ADC Payload with Reduced Bystander Killing. ChemMedChem 15 (24) (2020)

Fredrik Lehmann.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Fredrik Lehmann